Interview with Dirceu Barbano, Director, ANVISA
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
Address: Praia de Botafogo 501 1° Andar Bloco Corcovado 22250-040 Rio de Janeiro – RJ,Brazil
Tel: 55 21 3266 6200
Web: http://www1.actelion.com.br/br/index.page
In 2002, Actelion opened its first office in Latin America. Brazil was chosen as the venue due to different factors. The country is a medical centre in the region and is endowed with considerable structure, hospital and medical science. Brazil also possesses a strong political and social framework and is projected to be an important partner in international decisions, not only due its specific significance, such as increasing the performance of its economy.
In addition, it has development programs and conducts scientific and technological research.
Due to its growth potential in pharmaceuticals and its status as one of the largest research centers of reference in the continent, Brazil was chosen to as base of operations for Actelion in Latin America.
Tracleer, Zavesca
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to improve the Brazilian pharmaceutical…
In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the…
Sao Paulo state is responsible for some 85% of pharmaceutical production, and last week Minister Pimentel was in the city of Sao Paulo elaborating on his BrazilMaior plan with strategic…
Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is…
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
See our Cookie Privacy Policy Here
